Comparative analysis finds different infliximab induction dosing regimens do not alter one-year remission rates in pediatric Crohn's disease, suggesting standard dosing remains adequate.
Multiple studies in patients with Crohn's disease (CD) treated with anti-tumor necrosis factor alpha agents have shown that proactive therapeutic drug monitoring (TDM) during the maintenance phase leads to improved outcomes. We aimed to assess whether accelerated (IFX) administration during induction resulted in improved outcomes.
No takes yet. Share an insight, caveat, or question.
Marshanski et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: